| Overview |
| bs-13153R-Cy3 |
| FDPS Polyclonal Antibody, Cy3 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Rat |
| Human, Mouse, Dog, Cow, Sheep, Horse, Rabbit |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human FDPS |
| 201-300/419 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2224 |
| Cytoplasm |
| 2E,6E farnesyl diphosphate synthase; 6E-farnesyl diphosphate synthase; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; Farnesyl diphosphate synthetase; Farnesyl pyrophosphate synthase; Farnesyl pyrophosphate synthetase; Fdps; FPP synthase; FPP synthetase; FPPS; FPPS_HUMAN; FPS; Geranyltranstransferase. |
| FDPS is a 419 amino acid enzyme belonging to the FPP/GGPP synthetase family. Localized to cytoplasm and peroxisome, FDPS expression is regulated by phorbol esters and polyunsaturated fatty acids. FDPS assists in cholesterol biosynthesis, post-translational protein modifications and synthesis of steroid hormones in the isoprenoid pathway.FDPS catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FDPS is inactivated by interferon-induced RSAD2, which may result in the disruption of lipid rafts at the plasma membrane. Existing as a homodimer, FDPS may have anti-viral effects when inactivated by RSAD2. Reduced activity of FDPS in liver may partly be the cause of Zellweger syndrome and neonatal adrenoleukodystrophy, both of which are known to be peroxisomal deficiency diseases. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz